New drug combo aims to overcome resistance in lung cancer treatment
NCT ID NCT04895579
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested whether adding copanlisib to the standard immune therapy durvalumab is safe for people with stage III non-small cell lung cancer that cannot be removed by surgery. The study enrolled 11 participants who had already received chemotherapy and radiation. The main goal was to check for side effects and find the best dose, with a secondary look at how well the tumors responded.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Copanlisib (Aliqopa) and Durvalumab (Imfinzi)
What this could lead to
If this combination is safe and effective, it could offer a new option to improve outcomes for people with advanced lung cancer who are already on durvalumab.
What could go wrong
This is a very early phase 1 trial with only 11 participants, so results may not apply to everyone. The main goal is safety, not yet proof of benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Markey Cancer Center
Lexington, Kentucky, 40536, United States